INTERVIEW: ImmuPharma PLC New Phase III Lupuzor Trial Data Positive

ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the further analysis of the results from its pivotal Phase III trial of Lupuzor and final results. Tim talks us through the key take away highlights from the statement, explains the positive data that has emerged from further analysis, why predictive biomarkers important, updates us on the currently ongoing extension trial and tells us what the next steps are for the company.

 

ImmuPharma Plc is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange, focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. The company is led by a commercially focused Board and management team with extensive experience.

There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America). Current ‘standard of care’ treatments, including steroids and immunosuppressants, can potentially have either serious side effects for patients or limited effectiveness, with over 60% of patients not adequately treated. If Lupuzor™ is approved, it will be entering a market with the potential for multi-billion dollar sales.

Find more news, interviews, share price & company profile here for:

    You can also listen to our interviews on: 

    Share this interview

    Twitter
    LinkedIn
    Facebook
    Email
    WhatsApp
    Immupharma plc
    INTERVIEW: ImmuPharma PLC New Phase III Lupuzor Trial Data Positive

    Other Interviews

    More News

    Ask your questions

    Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

    I have questions